Ticker: LLY | Published: 2026-09-24
Lilly rallies on pipeline wins
Lilly is climbing sharply after the FDA approved its once-weekly insulin injection and it signed a collaboration deal with China's InnoCare worth up to $3.35 billion, outweighing a mixed report on an oral GLP-1 plant investment.
Sources: https://www.reuters.com/legal/litigation/us-fda-approves-lillys-once-weekly-insulin-injection-type-2-diabetes-2026-09-24/